Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.

Casado E, Garcia VM, Sánchez JJ, Gómez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, López RA, García-Cabezas MÁ, Burgos E, de Castro J, Belda-Iniesta C, López-Gómez M, Gómez-Raposo C, Zambrana F, Sereno M, Fernández-Martos C, Vázquez P, Lacal JC, González-Barón M, Cejas P. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1151-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.